Hiroaki Okamoto
Overview
Explore the profile of Hiroaki Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
425
Citations
6963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nosaka T, Naito T, Akazawa Y, Takahashi K, Matsuda H, Ohtani M, et al.
PLoS One
. 2025 Mar;
20(3):e0314581.
PMID: 40048440
To cure hepatitis B virus (HBV) infection, it is essential to elucidate the function of hepatocyte host factors in regulating the viral life cycle. Signaling and transcription activator of transcription...
2.
Liang Q, Cao B, Qiu L, Ma C, Matsumoto K, Okamoto H, et al.
Sci Rep
. 2025 Feb;
15(1):5825.
PMID: 39966447
In this study, perfluoroalkylated derivatives of benzoic acid S-6 and O-6 were designed and synthesized as supramolecular gelators using a simple one-step method. Both S-6 and O-6 could form gels...
3.
Shigenobu T, Taniguchi Y, Suzuki T, Tabuchi Y, Sato M, Odagiri K, et al.
BMC Cancer
. 2025 Jan;
25(1):121.
PMID: 39844071
Background: No study has directly compared the outcomes of surgery and concurrent chemoradiotherapy (cCRT) in patients with stage III non-small cell lung cancer (NSCLC) to date. This study aimed to...
4.
Nagashima S, Primadharsini P, Takahashi M, Nishiyama T, Murata K, Okamoto H
Pathogens
. 2025 Jan;
13(12.
PMID: 39770389
Hepatitis E virus (HEV) exists in two distinct forms: a non-enveloped form (neHEV), which is present in feces and bile, and a quasi-enveloped form (eHEV), found in circulating blood and...
5.
Hamakawa Y, Hirahara A, Hayashi A, Ito K, Shinohara H, Shiba A, et al.
BMC Cancer
. 2025 Jan;
25(1):17.
PMID: 39762819
Introduction: The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune...
6.
Tokito T, Yamada K, Ishii H, Takiguchi Y, Saito G, Minato K, et al.
Radiat Oncol
. 2025 Jan;
20(1):2.
PMID: 39755666
Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic...
7.
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39755169
Introduction: Osimertinib is the first-line treatment for patients with NSCLC who have EGFR mutations and favorable performance status (PS). Despite the increasing clinical data on osimertinib, evidence for its use...
8.
Taniguchi Y, Shigenobu T, Hayashi A, Hirahara A, Ito K, Shinohara H, et al.
Anticancer Res
. 2024 Dec;
44(12):5541-5549.
PMID: 39626937
Background/aim: Survival outcomes in patients with successfully resected non-small-cell lung cancer (NSCLC) are not well understood. Furthermore, the best treatment strategy for postoperative locoregional recurrence has not been established. Patients...
9.
Kobayashi T, Takahashi M, Ohta S, Hoshino Y, Yamada K, Jirintai S, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339876
The zoonotic transmission of hepatitis E virus (HEV) genotypes 3 (HEV-3) and 4 (HEV-4), and rabbit HEV (HEV-3ra) has been documented. Vaccination against HEV infection depends on the capsid (open...
10.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, et al.
Lancet Respir Med
. 2024 Aug;
12(11):877-887.
PMID: 39159638
Background: The combination of platinum-based chemotherapy and an antibody to PD-1 or to its ligand PD-L1, with or without an antibody to CTLA-4, has improved the survival of individuals with...